GlassScriptPhysician profile
William M Lindel
NPI 1558366278
$1,113.64
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $147 · 2021: $47.99 · 2022: $398 · 2023: $78.34 · 2024: $57.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.15 | 2019-2022 | |
| Pfizer INC. | $142.66 | 2019-2022 | |
| Astellas Pharma US INC | $142.57 | 2019-2024 | Veozah |
| Intuitive Surgical, INC. | $90.46 | 2022 | |
| Ethicon US, LLC | $58.03 | 2023-2024 | Enseal, Mega Soft |
| Therapeuticsmd, INC. | $39.52 | 2020-2022 | |
| Mission Pharmacal Company | $35.32 | 2019-2023 | Citranatal |
| Roche Diagnostics Corporation | $34.77 | 2019 | |
| Ferring Pharmaceuticals INC. | $31.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.24 | 2019 | |
| Exeltis, USA INC. | $21.20 | 2019 | |
| Hologic Sales and Service, LLC | $20.12 | 2024 | Coolseal Generator |
| Biohaven Pharmaceutical Holding Company LTD. | $19.79 | 2022 | |
| Daiichi Sankyo INC. | $18.89 | 2020 | |
| Evofem Biosciences, INC. | $17.15 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $15.16 | 2022 | |
| Merck Sharp & Dohme LLC | $15.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2023 | Trulance |
| Urovant Sciences INC | $14.47 | 2022 | |
| Avion Pharmaceuticals | $13.10 | 2019 | |
| Shield Therapeutics INC | $13.08 | 2023 | Accrufer |
| Vertical Pharmaceuticals, LLC | $12.95 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.47 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lindel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.